Inhibikase Therapeutics, Inc.
IKT Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$1.59
KIRA · Stoqly’s AI analyst, in plain words
- Inhibikase Therapeutics, Inc. had $3.7M of revenue in fiscal 2025. Over five years, revenue changed +39.7% a year on average.
- Its operating margin was −1,399.0%: of every 100 in sales, about −1,399 is left after running the business.
- Inhibikase Therapeutics, Inc. lost $48.3M in fiscal 2025.
- Free cash flow was −$27.8M in fiscal 2025, −748.3% of revenue.
- Inhibikase Therapeutics, Inc. has $218M more cash than debt.
Market cap
$278M
P/E
—
Revenue
$3.7M
Net income
−$48.3M
Free cash flow
−$27.8M
Operating margin
−1,399.0%
Inhibikase Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−1,299.0%
No. It lost money last year.
Does profit turn into cash?
−748.3%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Inhibikase Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 26, 2026
- Legal name
- Inhibikase Therapeutics, Inc.
- CIK
- 0001750149
Inhibikase Therapeutics, Inc. · IKT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $3.1M | $0.1M | $0.3M | $0.0M | $3.7M |
| Revenue growth | 343.9% | −96.0% | 111.1% | −100.0% | — |
| Net interest income | −$0.0M | $0.1M | $1.1M | $1.1M | $3.7M |
| Operating margin | −476.2% | −14,690.9% | −7,712.0% | — | −1,399.0% |
| Net income | −$14.8M | −$18.1M | −$19.0M | −$27.5M | −$48.3M |
| Net margin | −476.9% | −14,630.6% | −7,304.8% | — | −1,299.0% |
| Diluted EPS | −$0.81 | −$4.28 | −$3.16 | −$1.16 | −$0.49 |
| Cash | |||||
| Cash from operations | −$14.3M | −$17.4M | −$18.1M | −$19.1M | −$27.8M |
| Capital expenditure | $0.0M | $0.2M | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$14.3M | −$17.6M | −$18.1M | −$19.1M | −$27.8M |
| FCF margin | −461.1% | −14,258.0% | −6,947.9% | — | −748.3% |
| Share count change | 121.7% | −76.8% | 42.7% | 293.4% | 314.6% |
| Debt and strength | |||||
| Cash and short-term investments | $40.8M | $23.1M | $13.3M | $139M | $218M |
| Debt incl. finance leases | $0.2M | $0.1M | $0.4M | $0.1M | $0.0M |
| Shareholders' equity | $38.4M | $21.0M | $11.0M | $94.9M | $173M |
| Current ratio | 10.5x | 6.6x | 4.1x | 26.4x | 21.7x |
| Interest coverage | −742.0x | — | — | — | — |
| Returns and quality | |||||
| Return on equity | −61.4% | −60.7% | −118.9% | −52.0% | −36.0% |
| Return on tangible equity | −38.5% | −85.8% | −173.3% | −29.0% | −27.9% |
| Piotroski F-score | 3 | 3 | 2 | 4 | 4 |
| Altman Z'' | 11.3 | −0.0 | −16.2 | 27.9 | 23.6 |
Insiders bought, 12 months
$3.0M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Inhibikase Therapeutics, Inc. · IKT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.59 a share, the company is worth $278M.
Source: SEC EDGAR XBRL filings (CIK 0001750149). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.